基本情報
研究分野
1学歴
2-
2006年4月 - 2012年3月
-
1997年4月 - 2003年3月
受賞
3論文
162-
Case Reports in Oncology 10(1) 175-181 2017年1月6日 査読有り
-
Ultrasound in Medicine & Biology 43 S179-S179 2017年
-
Yonago Acta Medica 60(4) 220-226 2017年 査読有り
-
Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology 28(6) 522-524 2016年11月1日 査読有り
-
AURIS NASUS LARYNX 43(5) 579-583 2016年10月 査読有り
-
YONAGO ACTA MEDICA 59(3) 241-247 2016年9月 査読有り
-
PITX1 is a novel predictor of the response to chemotherapy in head and neck squamous cell carcinoma.Molecular and clinical oncology 5(1) 89-94 2016年7月 査読有りThe pituitary homeobox 1 (PITX1) protein is essential for developmental processes in humans. Previously, PITX1 was identified as a possible tumor suppressor gene in various types of human carcinoma. However, the association between PITX1 and human head and neck squamous cell carcinoma (HNSCC) remains to be elucidated. Immunohistochemical analysis was performed to examine the expression levels of PITX1 in 47 cases of HNSCC, and in 4 control cases. The expression of p53 was also examined in these cases. The labeling indices (LIs) were calculated, and the correlations between clinical factors (chemosensitivity, prognosis and the degree of differentiation) and the LIs were assessed. The PITX1 LI in HNSCC was 27.4±14.5%, which was significantly lower compared with the LIs of the control samples: 76.9±6.97% (P<0.05). Additionally, the PITX1 LIs were 39.9±6.2, 26.9±16.9 and 24.2±11.8% in the complete response (CR), partial response (PR), stable disease or progressive disease (SD/PD) groups, respectively. The PITX1 LI in the CR group revealed the highest result between the all groups, and it was significantly greater compared with that in the SD/PD group (P<0.01). The p53 LIs were 24.5±19.9, 25.7±16.9 and 19.8±13.8 in the CR, PR and SD/PD groups, respectively (P>0.05). Neither the PITX1 nor the p53 LIs were a statistically significant indicator of the prognosis. PITX1 is a candidate tumor suppressor gene and a possible predictive biomarker of chemosensitivity of human HNSCC.
-
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY 21(2) 402-408 2016年4月 査読有り
-
Journal of Robotic Surgery 10(1) 11-17 2016年3月1日 査読有り
-
Acta Oto-Laryngologica Case Reports 1(1) 113-118 2016年1月
-
Practica Oto-Rhino-Laryngologica 109(12) 843-848 2016年 査読有り
-
Practica Otologica, Supplement 145 76-77 2016年 査読有り
-
ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY HEAD AND NECK SURGERY 78(5) 252-258 2016年 査読有り
-
Journal of Robotic Surgery 9(4) 315-319 2015年12月1日 査読有り
-
Journal of Robotic Surgery 9(4) 347-354 2015年12月1日 査読有り
-
ULTRASOUND IN MEDICINE AND BIOLOGY 41(9) 2326-2332 2015年9月 査読有り
-
Japanese Journal of Head and Neck Cancer 41(1) 83-89 2015年5月12日 査読有り
-
YONAGO ACTA MEDICA 58(1) 9-13 2015年3月 査読有り
-
Practica Otologica, Supplement 141 106-107 2015年 査読有り
-
Practica Oto-Rhino-Laryngologica 108(9) 713-718 2015年 査読有り
-
Practica Oto-Rhino-Laryngologica 108(6) 483-488 2015年 査読有り
-
Pan European Voice Conference : Pevoc 11 Abstract Book 104 2015年 査読有り
-
Pan European Voice Conference : Pevoc 11 Abstract Book 104 2015年 査読有り
-
Journal of Thyroid Research 2015 164548 2015年 査読有り
-
BIOMED RESEARCH INTERNATIONAL 2015 569367 2015年 査読有り
-
Nihon Jibiinkoka Gakkai kaiho 117(7) 887-892 2014年7月 査読有り
-
ENDOCRINE JOURNAL 61(6) 615-621 2014年6月 査読有り
MISC
14-
Yonago acta medica 62(1) 67-76 2019年3月Background: Adenoid cystic carcinoma (ACC) is a relatively rare malignant neoplasm that occurs in salivary glands and various other organs. Recent studies have revealed that a significant proportion of ACCs harbor gene alterations involving MYB or MYBL1 (mostly fusions with NFIB) in a mutually-exclusive manner. However, its clinical significance remains to be well-established. Methods: We investigated clinicopathological and molecular features of 36 ACCs with special emphasis on the significance of MYBL1 alterations. Reverse-transcription polymerase-chain reaction (RT-PCR) and fluorescence in-situ hybridization (FISH) were performed to detect MYB/MYBL1-NFIB fusions and MYBL1 alterations, respectively. Immunohistochemistry was performed to evaluate MYB expression in the tumors. The results were correlated with clinicopathological profiles of the patients. Results: RT-PCR revealed MYB-NFIB and MYBL1-NFIB fusions in 10 (27.8%) and 7 (19.4%) ACCs, respectively, in a mutually-exclusive manner. FISH for MYBL1 rearrangements was successfully performed in 11 cases, and the results were concordant with those of RT-PCR. Immunohistochemically, strong MYB expression was observed in 23 (63.9%) tumors, none of which showed MYBL1 alterations. Clinicopathologically, a trend of a better disease-specific survival was noted in patients with MYBL1 alterations than in those with MYB-NFIB fusions and/or strong MYB expression; however, the difference was not significant. Interestingly, we found tumors with MYBL1 alterations significantly frequently occurred in the mandibular regions (P = 0.012). Moreover, literature review revealed a similar tendency in a previous study. Conclusion: Our results suggest that there are some biological or etiological differences between ACCs with MYB and MYBL1 alterations. Moreover, the frequent occurrence of MYBL1-associated ACC in the mandibular regions suggests that MYB immunohistochemistry is less useful in diagnosing ACCs arising in these regions. Further studies are warranted to verify our findings.
共同研究・競争的資金等の研究課題
5-
文科省科学研究費:基盤C 2018年4月 - 2020年3月
-
文科省科学研究費:基盤C 2017年4月 - 2019年3月
-
文科省科学研究費:若手B 2016年4月 - 2017年3月
-
厚労省科学研究費 2013年4月 - 2016年3月
-
文科省科学研究費:若手B 2014年4月 - 2015年3月